Published in Ann Rheum Dis on August 01, 2001
Anti-TNF immunotherapy reduces CD8+ T cell-mediated antimicrobial activity against Mycobacterium tuberculosis in humans. J Clin Invest (2009) 2.12
How tumour necrosis factor blockers interfere with tuberculosis immunity. Clin Exp Immunol (2010) 1.48
Infiltration of the synovial membrane with macrophage subsets and polymorphonuclear cells reflects global disease activity in spondyloarthropathy. Arthritis Res Ther (2005) 1.21
Therapy of ankylosing spondylitis and other spondyloarthritides: established medical treatment, anti-TNF-alpha therapy and other novel approaches. Arthritis Res (2002) 1.21
Cellular and humoral mechanisms involved in the control of tuberculosis. Clin Dev Immunol (2012) 1.16
Anti-tumour necrosis factor alpha therapy for ankylosing spondylitis: international experience. Ann Rheum Dis (2002) 1.02
Cytokines in the seronegative spondyloarthropathies and their modification by TNF blockade: a brief report and literature review. Ann Rheum Dis (2003) 0.97
Th2 mediated regulation in RA and the spondyloarthropathies. Ann Rheum Dis (2002) 0.96
Association of cytokine and matrix metalloproteinase profiles with disease activity and function in ankylosing spondylitis. Arthritis Res Ther (2012) 0.94
Cytokine and chemokine receptor profile of peripheral blood mononuclear cells during treatment with infliximab in patients with active rheumatoid arthritis. Ann Rheum Dis (2004) 0.94
Ankylosing spondylitis: introductory comments on its diagnosis and treatment. Ann Rheum Dis (2002) 0.90
Preferential type 1 chemokine receptors and cytokine production of CD28- T cells in ankylosing spondylitis. Ann Rheum Dis (2005) 0.85
The transition of acute to chronic bowel inflammation in spondyloarthritis. Nat Rev Rheumatol (2012) 0.81
Paradoxical reactions under TNF-α blocking agents and other biological agents given for chronic immune-mediated diseases: an analytical and comprehensive overview. RMD Open (2016) 0.81
Treatment of active spondyloarthropathy with infliximab, the chimeric monoclonal antibody to tumour necrosis factor alpha. Ann Rheum Dis (2001) 0.78
Aberrant regulation of interleukin-12 receptor beta2 chain on type 1 cytokine-stimulated T lymphocytes in type 1 diabetes. Immunology (2005) 0.77
Activation-Induced Killer Cell Immunoglobulin-like Receptor 3DL2 Binding to HLA-B27 Licenses Pathogenic T Cell Differentiation in Spondyloarthritis. Arthritis Rheumatol (2016) 0.77
Infliximab in the treatment of ankylosing spondylitis. Biologics (2007) 0.76
Management of ankylosing spondylitis with infliximab. Open Access Rheumatol (2009) 0.75
The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum (1988) 111.05
TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties. Annu Rev Immunol (1989) 31.72
Functional diversity of helper T lymphocytes. Nature (1996) 18.09
The European Spondylarthropathy Study Group preliminary criteria for the classification of spondylarthropathy. Arthritis Rheum (1991) 11.66
Yersinia antigens in synovial-fluid cells from patients with reactive arthritis. N Engl J Med (1989) 3.68
Salmonella lipopolysaccharide in synovial cells from patients with reactive arthritis. Lancet (1990) 3.55
Cytokine patterns in the pathogenesis of human leishmaniasis. J Clin Invest (1993) 3.15
Th1/Th2 cytokine balance in arthritis. Arthritis Rheum (1997) 3.11
Selective reduction of V alpha 14+ NK T cells associated with disease development in autoimmune-prone mice. J Immunol (1996) 2.83
Detection of Chlamydia trachomatis DNA in joints of reactive arthritis patients by polymerase chain reaction. Lancet (1992) 1.83
Chronic exposure to tumor necrosis factor (TNF) in vitro impairs the activation of T cells through the T cell receptor/CD3 complex; reversal in vivo by anti-TNF antibodies in patients with rheumatoid arthritis. J Clin Invest (1994) 1.81
Effects of a loading dose regimen of three infusions of chimeric monoclonal antibody to tumour necrosis factor alpha (infliximab) in spondyloarthropathy: an open pilot study. Ann Rheum Dis (2000) 1.79
IL-12 regulates T helper type 1 cytokine responses in human infectious disease. J Immunol (1994) 1.65
Differential expression of NK T cell V alpha 24J alpha Q invariant TCR chain in the lesions of multiple sclerosis and chronic inflammatory demyelinating polyneuropathy. J Immunol (2000) 1.63
Regulation of interleukin 10 release by tumor necrosis factor in humans and chimpanzees. J Exp Med (1994) 1.63
Pathogenesis of spondylarthropathies. Persistent bacterial antigen, autoimmunity, or both? Arthritis Rheum (1995) 1.52
Differential Th1/Th2 cytokine patterns in chronic arthritis: interferon gamma is highly expressed in synovium of rheumatoid arthritis compared with seronegative spondyloarthropathies. Ann Rheum Dis (2000) 1.44
Elevated interleukin-10 levels in patients with rheumatoid arthritis. Arthritis Rheum (1995) 1.42
Predominance of Th1-type T cells in synovial fluid of patients with Yersinia-induced reactive arthritis. Eur J Immunol (1992) 1.36
Long-term follow-up of the changes in circulating cytokines, soluble cytokine receptors, and white blood cell subset counts in patients with rheumatoid arthritis (RA) after monoclonal anti-TNF alpha antibody therapy. J Clin Immunol (1999) 1.28
Crucial role of interleukin-10/interleukin-12 balance in the regulation of the type 2 T helper cytokine response in reactive arthritis. Arthritis Rheum (1997) 1.27
High level of interleukin-10 production by the activated T cell population within the rheumatoid synovial membrane. Arthritis Rheum (1995) 1.26
Interleukin-10 functions as an antiinflammatory cytokine in rheumatoid synovium. Arthritis Rheum (1996) 1.22
Response to methotrexate in early rheumatoid arthritis is associated with a decrease of T cell derived tumour necrosis factor alpha, increase of interleukin 10, and predicted by the initial concentration of interleukin 4. Ann Rheum Dis (2000) 1.16
Treatment with monoclonal anti-tumor necrosis factor alpha antibody results in an accumulation of Th1 CD4+ T cells in the peripheral blood of patients with rheumatoid arthritis. Arthritis Rheum (1999) 1.10
Low secretion of tumor necrosis factor alpha, but no other Th1 or Th2 cytokines, by peripheral blood mononuclear cells correlates with chronicity in reactive arthritis. Arthritis Rheum (1999) 1.09
Anti-tumor necrosis factor modulates anti-CD3-triggered T cell cytokine gene expression in vivo. J Clin Invest (1994) 1.01
The elevated ratio of interferon gamma-/interleukin-4-positive T cells found in synovial fluid and synovial membrane of rheumatoid arthritis patients can be changed by interleukin-4 but not by interleukin-10 or transforming growth factor beta. Rheumatology (Oxford) (1999) 0.97
IL-10 plasma levels correlate with disease activity in spondyloarthropathy. J Rheumatol (1997) 0.94
Protective role of NK1.1+ cells in experimental Staphylococcus aureus arthritis. Clin Exp Immunol (1999) 0.92
V alpha 14+ NK T cells: a novel lymphoid cell lineage with regulatory function. J Allergy Clin Immunol (1996) 0.89
Diabetes prone BB rats are severely deficient in natural killer T cells. Autoimmunity (1999) 0.89
Contrasting cytokine profiles in the synovium of different forms of juvenile rheumatoid arthritis and juvenile spondyloarthropathy: prominence of interleukin 4 in restricted disease. J Rheumatol (1998) 0.88
Increased interleukin-4 production by NK T cells in systemic lupus erythematosus. Clin Immunol (1999) 0.87
Natural killer T cells: a potent cytokine-producing cell population. Eur Cytokine Netw (1997) 0.85
Cytokines and arthritis: is the Th1/Th2 paradigm useful for understanding pathogenesis? J Rheumatol (1998) 0.81
Decreased peripheral blood T cell cytokine gene expression in rheumatoid arthritis. Scand J Rheumatol (1999) 0.77
The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection. Ann Rheum Dis (2009) 8.37
The Assessment of SpondyloArthritis International Society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general. Ann Rheum Dis (2010) 5.24
The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part I): classification of paper patients by expert opinion including uncertainty appraisal. Ann Rheum Dis (2009) 3.32
LY2439821, a humanized anti-interleukin-17 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: A phase I randomized, double-blind, placebo-controlled, proof-of-concept study. Arthritis Rheum (2010) 2.99
Specific presence of intracellular citrullinated proteins in rheumatoid arthritis synovium: relevance to antifilaggrin autoantibodies. Arthritis Rheum (2001) 2.96
Assessment of enthesitis in ankylosing spondylitis. Ann Rheum Dis (2003) 2.48
ASDAS, a highly discriminatory ASAS-endorsed disease activity score in patients with ankylosing spondylitis. Ann Rheum Dis (2008) 2.37
New criteria for inflammatory back pain in patients with chronic back pain: a real patient exercise by experts from the Assessment of SpondyloArthritis international Society (ASAS). Ann Rheum Dis (2009) 2.22
Relative value of erythrocyte sedimentation rate and C-reactive protein in assessment of disease activity in ankylosing spondylitis. J Rheumatol (1999) 2.21
Rheumatoid factor, but not anti-cyclic citrullinated peptide antibodies, is modulated by infliximab treatment in rheumatoid arthritis. Ann Rheum Dis (2004) 2.18
Rheumatoid factor and anticitrullinated protein antibodies in rheumatoid arthritis: diagnostic value, associations with radiological progression rate, and extra-articular manifestations. Ann Rheum Dis (2004) 2.15
Ileocolonoscopy in seronegative spondylarthropathy. Gastroenterology (1989) 2.06
A dose adjustment in patients with rheumatoid arthritis not optimally responding to a standard dose of infliximab of 3 mg/kg every 8 weeks can be effective: a Belgian prospective study. Rheumatology (Oxford) (2005) 2.05
Work status and productivity costs due to ankylosing spondylitis: comparison of three European countries. Ann Rheum Dis (2002) 2.02
The evolution of spondyloarthropathies in relation to gut histology. II. Histological aspects. J Rheumatol (1995) 1.99
Automated neonatal seizure detection mimicking a human observer reading EEG. Clin Neurophysiol (2008) 1.96
Association between polymorphism in IgG Fc receptor IIIa coding gene and biological response to infliximab in Crohn's disease. Aliment Pharmacol Ther (2004) 1.87
Effects of a loading dose regimen of three infusions of chimeric monoclonal antibody to tumour necrosis factor alpha (infliximab) in spondyloarthropathy: an open pilot study. Ann Rheum Dis (2000) 1.79
Repeated infusions of infliximab, a chimeric anti-TNFalpha monoclonal antibody, in patients with active spondyloarthropathy: one year follow up. Ann Rheum Dis (2002) 1.76
Immunomodulatory effects of anti-tumor necrosis factor alpha therapy on synovium in spondylarthropathy: histologic findings in eight patients from an open-label pilot study. Arthritis Rheum (2001) 1.70
Serum IgG, IgM, and IgA levels in ankylosing spondylitis. Ann Rheum Dis (1973) 1.65
Histopathology of intestinal inflammation related to reactive arthritis. Gut (1987) 1.64
Rapid improvement of bone metabolism after infliximab treatment in Crohn's disease. Aliment Pharmacol Ther (2004) 1.62
Ileocolonoscopic findings in seronegative spondylarthropathies. Br J Rheumatol (1988) 1.55
Validation of a new automated neonatal seizure detection system: a clinician's perspective. Clin Neurophysiol (2011) 1.52
Defining disease activity in ankylosing spondylitis: is a combination of variables (Bath Ankylosing Spondylitis Disease Activity Index) an appropriate instrument? Rheumatology (Oxford) (1999) 1.51
The evolution of spondyloarthropathies in relation to gut histology. III. Relation between gut and joint. J Rheumatol (1995) 1.51
Comparative analysis of detoxification enzymes in Acyrthosiphon pisum and Myzus persicae. Insect Mol Biol (2010) 1.48
Comparative study of the synovial histology in rheumatoid arthritis, spondyloarthropathy, and osteoarthritis: influence of disease duration and activity. Ann Rheum Dis (2000) 1.47
Crohn's disease with adenocarcinoma and dysplasia. Macroscopical, histological, and immunohistochemical aspects of two cases. Am J Surg Pathol (1989) 1.47
Serum levels of IgG, IgM, and IgA in rheumatoid arthritis. Ann Rheum Dis (1968) 1.45
Offering excess oocyte aspiration and vitrification to patients undergoing stimulated artificial insemination cycles can reduce the multiple pregnancy risk and accumulate oocytes for later use. Hum Reprod (2010) 1.45
Gut inflammation in the spondyloarthropathies: clinical, radiologic, biologic and genetic features in relation to the type of histology. A prospective study. J Rheumatol (1991) 1.45
The evolution of spondyloarthropathies in relation to gut histology. I. Clinical aspects. J Rheumatol (1995) 1.44
Tuberculin skin test versus interferon-gamma release assays for the diagnosis of tuberculosis infection. Acta Clin Belg (2014) 1.43
Etiological factors and underlying conditions in patients with leucocytoclastic vasculitis. Clin Exp Rheumatol (1997) 1.42
Crohn's disease associated with spondyloarthropathy: effect of TNF-alpha blockade with infliximab on articular symptoms. Lancet (2000) 1.42
Gastric emptying of solids in cirrhotic and peritoneal dialysis patients: influence of peritoneal volume load. Eur J Gastroenterol Hepatol (2002) 1.41
A comparative study of the usefulness of the Bath Ankylosing Spondylitis Functional Index and the Dougados Functional Index in the assessment of ankylosing spondylitis. J Rheumatol (1999) 1.40
Human cartilage gp-39+,CD16+ monocytes in peripheral blood and synovium: correlation with joint destruction in rheumatoid arthritis. Arthritis Rheum (2000) 1.39
A positive response to infliximab in Crohn disease: association with a higher systemic inflammation before treatment but not with -308 TNF gene polymorphism. Scand J Gastroenterol (2002) 1.38
Spondyloarthropathy is underestimated in inflammatory bowel disease: prevalence and HLA association. J Rheumatol (2000) 1.37
Needle arthroscopy of the knee with synovial biopsy sampling: technical experience in 150 patients. Clin Rheumatol (1999) 1.36
Rituximab in diffuse cutaneous systemic sclerosis: an open-label clinical and histopathological study. Ann Rheum Dis (2010) 1.34
Characterisation of human knee meniscus cell phenotype. Osteoarthritis Cartilage (2005) 1.34
Specific antinuclear antibodies are associated with clinical features in systemic lupus erythematosus. Ann Rheum Dis (2004) 1.32
Physical function in ankylosing spondylitis is independently determined by both disease activity and radiographic damage of the spine. Ann Rheum Dis (2008) 1.32
Anti-citrullinated peptide antibodies may occur in patients with psoriatic arthritis. Ann Rheum Dis (2005) 1.31
Systematic safety follow up in a cohort of 107 patients with spondyloarthropathy treated with infliximab: a new perspective on the role of host defence in the pathogenesis of the disease? Ann Rheum Dis (2003) 1.31
Radiological scoring methods in ankylosing spondylitis: reliability and sensitivity to change over one year. J Rheumatol (1999) 1.31